Palisade Bio, Inc. (PALI) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$1.99
Price Target
$1.50
Target Range
$1.50 — $1.50
Analyst Rating
Buy
Forward P/E—
Trailing P/E-6.6x
Forward PEG—
Implied Growth+32.7%
Median Target$1.50
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$2
-24.6%
Consensus
$2
-24.6%
Bull Case
$2
-24.6%
PALI Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Palisade Bio, Inc. (PALI) has a Wall Street consensus price target of $1.50, based on estimates from 3 covering analysts. With the stock currently trading at $1.99, this represents a potential downside of -24.6%. The company has a market capitalization of $111M.
Analyst price targets range from a low of $1.50 to a high of $1.50, representing a 0% spread in expectations. The median target of $1.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PALI trades at a trailing P/E of -6.6x. Analysts expect EPS to grow +32.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+70.0%
Avg Forward P/E25.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 HALOHalozyme Therapeutics, Inc. | $7.7B | $65.19 | $78.33 | +20.2% | Buy | 8.1x | 27 |
 CHRSCoherus Oncology, Inc. | $213M | $1.76 | $6.02 | +242.0% | Buy | — | 16 |
 PRTAProthena Corporation plc | $567M | $10.53 | $19.00 | +80.4% | Buy | 42.7x | 28 |
 VNDAVanda Pharmaceuticals Inc. | $378M | $6.39 | $14.17 | +121.8% | Buy | — | 19 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 PTGXProtagonist Therapeutics, Inc. | $6.4B | $98.85 | $116.75 | +18.1% | Buy | 30.6x | 26 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 CRLCharles River Laboratories International, Inc. | $9.0B | $181.94 | $205.43 | +12.9% | Buy | 16.4x | 36 |
 IQVIQVIA Holdings Inc. | $30.3B | $178.64 | $225.63 | +26.3% | Buy | 14.1x | 44 |
Upside Potential Comparison
CHRSVNDAPRTAINVANKTRACADIQVHALOSee PALI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PALI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PALI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPALI — Frequently Asked Questions
Quick answers to the most common questions about buying PALI stock.
What is the PALI stock price target for 2026?
PALI's consensus price target is $1.5, -24.6% below the current price of $1.99. The 3 analysts tracking PALI see downside risk at present valuations.
Is PALI a buy, sell, or hold?
PALI has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $1.5 implies -24.6% downside from current levels.
Is PALI stock overvalued or undervalued?
PALI's current price is $1.99 with a consensus target of $1.5 (-24.6% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can PALI stock go?
The most bullish Wall Street analyst has a price target of $1.5 for PALI, while the most conservative target is $1.5. The consensus of $1.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PALI stock?
PALI is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PALI stock forecast?
The 12-month PALI stock forecast based on 3 Wall Street analysts shows a consensus price target of $1.5, with estimates ranging from $1.5 (bear case) to $1.5 (bull case). The median consensus rating is "Buy".
Should I buy PALI stock?
Analysts are cautious on PALI, with 0 Sell ratings and a price target of $1.5 (-24.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PALI price targets vary so much?
PALI analyst price targets range from $1.5 to $1.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1.5 consensus represents the middle ground.